Table 1 Summary of miRNA drugs for cancer in preclinical or clinical trials.
From: MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies
Drug | MiRNA | Drug type | Delivery & combination | Phase | ClinicalTrials.gov Identifier | Cancer type |
|---|---|---|---|---|---|---|
MRX34 | miR-34a | Double-stranded mimic | Liposome nanoparticle | Phase 1 (Terminated) | NCT01829971 | Liver cancer, SCLC, lymphoma, melanoma, renal cell carcinoma, NSCLC |
Liposome nanoparticle + Dexamethasone | Phase 1 (Withdrawn) | NCT02862145 | Melanoma | |||
TargomiR | miR-16 | Double-stranded synthetic mimic | Bacterial minicell (EDVs) | Phase 1 (Completed) | NCT02369198 | MPM, NSCLC |
MRG-106 (Cobomarsen) | miR-155 | LNA-based inhibitor | N/A | Phase 1 (Completed) | NCT02580552 | CTCL, CLL, DLBCL, ATLL |
Phase 2 (Early termination) | NCT03713320 | CTCL | ||||
INT-1B3 | miR-193a-3p | Mimic (1B3) | Lipid nanoparticle (LNP) | Phase 1 (Recruiting) | NCT04675996 | TNBC, NSCLC, melanoma, colon cancer, HCC |
TTX-MC138 | miR-10b | Inhibitor (Antisense oligo) | Dextran-coated iron oxide nanoparticles | Preclinical | N/A | Metastatic breast cancer, GBM, pancreatic cancer, SCLC, osteosarcoma |
RGLS5579 | miR-10b | Inhibitor (Antisense oligo) | Unknown | Preclinical | N/A | GBM |
